Skip to content

The effect of dexmedetomidine on epidural-related maternal fever, a randomized controlled study

The effect of dexmedetomidine on epidural-related maternal fever, a randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070793
Enrollment
Unknown
Registered
2023-04-23
Start date
2023-04-20
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epidural related materna fever

Interventions

Group Dexmedetomidine:0.4ug/ml dexmedetomidine and 0.075%ropivacaine for labor analgesia
Group Sufentanil:0.3ug/ml sufentanil and 0.075%ropivacaine for labor analgesia

Sponsors

Shanghai First Maternity and Infant Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: ASA class II, gestational weeks > 37 weeks, 18y 5 (VNRS 0-10, where 0 = no pain and 10 = worst pain imaginable) at the request of epidural analgesia were eligible.

Exclusion criteria

Exclusion criteria: Contraindication to neuraxial anesthesia (e.g., bleeding and coagulation disorders, allergy to local anesthetic drugs); accidental dural puncture; allergy to sufentanil, dexmedetomidine, or ropivacaine; having received opioids or sedatives 4 h prior to labor analgesia and delivery within 4 h after the administration of labor analgesia.

Design outcomes

Primary

MeasureTime frame
the incidence of fever;

Secondary

MeasureTime frame
IL-6;ccf-mtDNA;

Countries

China

Contacts

Public Contactzhou shuangqiong

Shanghai First Maternity and Infant Hospital

zsq628628@163.com+86 13916174158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026